E. Rankin

Deterioration of renal function in a patient with lupus.

D. Isenberg, E. Rankin, G. Nield, 1994, Annals of the rheumatic diseases.

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.

G. Kingsley, D. Isenberg, E. Choy, 1995, British journal of rheumatology.

Progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis and polymyositis.

F. Scaravilli, E. Rankin, 1995, The Journal of rheumatology.

IgA deficiency and SLE: prevalence in a clinic population and a review of the literature

D. Isenberg, E. Rankin, 1997, Lupus.

The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.

G. Kingsley, D. Isenberg, R. Eastell, 1999, Journal of Rheumatology.